After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Get the (ABPI) Report Here
Trade with Jim Cramer 14 Days FREE
More on the Roche deal for Genentech, the value in Gilead and much more.
Shares plunge 67.6% after the company chooses to halt development of the drug SinuNase.
Accentia climbs on SinuNase study results.
Telik tumbles on startling results for its experimental cancer treatment Telcyta.
Sigma Designs and GTX trade lower on negative analyst research.
Genomic Health jumps.
A.P. Pharma dives.
Shares soar some 59% on postive cancer remission data for BiovaxID.
Accentia Biopharmaceuticals surges.
Osiris Therapeutics is stronger.
An upgrade lifts BioMarin.
The four-year agreement is for $25 million in exchangeable convertible debentures.
BioDelivery Sciences sinks after the FDA sends a nonapprovable letter for the nausea drug Emezine.
Exact Sciences rises nearly 50%.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.